A
Alcista
Alcista · 25%AZN
$82.29
Precio del escenario
$171.490
-1.080 (-0.63%)Al cierre
Loading chart…
- Máximo
- 171.750
- Apertura
- 171.280
- Precio medio ponderado por volumen
- 170.92
- Volumen
- 3.69M
- Capitalización
- 242.40B
- Mínimo
- 169.510
- Importe
- 630.92M
- EV/EBITDA, TTM
- 13.30
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
Análisis de IA of AstraZeneca PLC (AZN)
ComprarAstraZeneca PLC appears to be a good buy right now due to its current price of $171.49, which is below the average analyst price target of $218.50. The stock has a strong forward P/E ratio of 14.62, suggesting it is undervalued compared to its earnings potential. Additionally, the gross margin stands at 81.25%, indicating robust profitability. However, the main risk is the RSI of 71.20, which suggests the stock is nearing overbought territory, potentially leading to a price correction.
Recomendaciones de analistas (5)
+24.58% de potencial alcista
Comprar
4 Comprar
1 Mantener
0 Vender
Actual: 171.49
Mínimo
157.61
Promedio
213.64
Máximo
252.18
Citi
Comprar
—
2026-10-06
Citi
2026-10-06
Precio objetivo
—
Comprar
Berenberg
Comprar
—
2026-09-15
Berenberg
2026-09-15
Precio objetivo
—
Comprar
Deutsche Bank
Mantener
—
2026-09-15
Deutsche Bank
2026-09-15
Precio objetivo
—
Mantener
HSBC
Mantener
—
2026-09-10
HSBC
2026-09-10
Precio objetivo
—
Mantener
RBC Capital
Superar al mercado
—
2026-09-08
RBC Capital
2026-09-08
Precio objetivo
—
Superar al mercado
Métricas de valoración
El PER previsto actual de AstraZeneca PLC (AZN) es 14.62, frente a su media de 5 años de 16.34.
Escenarios de precio de Alphio AI para AZN
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con AZN en cartera
Cronología de eventos
Noticias
9.010-24NewsfilterIMFINZI Plus EV Shows Significant Survival Benefits in Bladder Cancer
9.010-24NewsfilterAmgen's New Drug Significantly Extends Lung Cancer Patients' Survival
9.010-24CNBCAmgen's Drug Significantly Extends Survival for Lung Cancer Patients
- 9.010-24Newsfilter
IMFINZI Combination Therapy Achieves Landmark Survival Rates in Small Cell Lung Cancer
2.010-21FoolAlnylam Pharmaceuticals Shares Plunge 40% Amidst Profitability Concerns
Preguntas frecuentes sobre AZN, respondidas por Alphio AI
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
AstraZeneca PLC appears to be a good buy right now due to its current price of $171.49, which is below the average analyst price target of $218.50. The stock has a strong forward P/E ratio of 14.62, suggesting it is undervalued compared to its earnings potential. Additionally, the gross margin stands at 81.25%, indicating robust profitability. However, the main risk is the RSI of 71.20, which suggests the stock is nearing overbought territory, potentially leading to a price correction.
5 analysts cover AZN: 4 rate it Buy, 1 Hold and 0 Sell. The average price target is 213.64.
Comunidad
Más ↗
Oracle and AstraZeneca are exploring AI to address the clinical-trial recruitment challenge. $ORCL $AZN
Mostrar más
AstraZeneca and Oracle launch global AI collaboration to advance clinical trial optimisation and support better patient outcomes Partnership aims to advance solutions to improve care pathways, clinical trial matching, safety monitoring, and guideline-directed care AstraZeneca and Oracle Health and Life Sciences today announced a unique collaboration to leverage AstraZeneca's scientific, clinical development and regulatory expertise with Oracle's real-world data, cloud infrastructure, and AI-enabled clinical capabilities to accelerate clinical research and bring evidence-driven insights into care workflows to accelerate clinical trial optimisation and help more patients receive the right care sooner. $AZN $ORCL
Mostrar más
$SMMT just landed a major combo opportunity for ivonescimab — and Datroway is the key. Summit is teaming with AstraZeneca ($AZN) and Daiichi Sankyo to evaluate ivonescimab with Datroway, a TROP2-targeted ADC jointly developed and commercialized by Daiichi and AstraZeneca. The initial focus is a Phase III study in first-line TNBC, while the collaboration plans to evaluate the combo across multiple solid tumors, including breast and lung cancers. Latest SMMT news here
Mostrar más
$SMMT $AZN Citi raised its price target on Summit Therapeutics (SMMT) to $43 from $40 and keeps a Buy rating on the shares after the company announced a $2B investment from AstraZeneca (AZN). AstraZeneca's $2B investment in convertible preferred shares is equivalent to $18.36 per common share, representing a 19% premium to Summit's latest closing price, the analyst tells investors in a research note. Citi views the deal as a "de-risking event" that removes Summit's financing overhang.
Mostrar más
$SMMT is up 20% after hours on a $2B investment from $AZN. These big January call spreads are still in the OI.
Mostrar másEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.